|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression decreases expression |
EXP ISO |
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine Pravastatin results in decreased expression of ABCA1 |
CTD |
PMID:17526932 PMID:19461118, PMID:17526932 |
RGD:2308820 |
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions affects import |
ISO |
Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] ABCB11 protein affects the import of Pravastatin |
CTD |
PMID:15901796 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCB4 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export increases expression multiple interactions affects transport |
ISO EXP |
ABCC2 protein affects the export of Pravastatin Pravastatin results in increased expression of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the transport of Pravastatin |
CTD |
PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Pravastatin |
CTD |
PMID:17939016 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ABCD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:225,335,708...225,389,120
Ensembl chr 2:225,335,718...225,389,120
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects export increases activity |
ISO |
ABCG2 protein affects the export of Pravastatin Pravastatin results in increased activity of ABCG2 protein |
CTD |
PMID:15901800 PMID:27475308 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACAA1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:127,836,235...127,845,296
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:70,733,872...70,762,395
Ensembl chr18:70,733,872...70,762,395
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:58,166,990...58,195,884
Ensembl chr 8:58,166,990...58,195,884
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACOT1 mRNA Pravastatin results in decreased expression of ACOT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:107,485,088...107,493,082
Ensembl chr 6:107,485,249...107,493,798
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOT12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:20,857,056...20,901,656
Ensembl chr 2:20,857,202...20,901,659
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
affects expression |
ISO |
Pravastatin affects the expression of ACOT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:107,460,596...107,468,324
Ensembl chr 6:107,460,668...107,467,487
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:107,531,508...107,537,446
Ensembl chr 6:107,531,528...107,536,789
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACSF2 mRNA Pravastatin results in decreased expression of ACSF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:82,284,719...82,326,771
Ensembl chr10:82,284,720...82,326,771
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:48,937,456...49,003,898
Ensembl chr16:48,937,456...49,003,246
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:56,674,072...56,677,084
Ensembl chr19:56,674,074...56,677,084
|
|
G |
Adamdec1 |
ADAM-like, decysin 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of ADAMDEC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:49,485,604...49,521,638
Ensembl chr15:49,485,611...49,505,553
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ADH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ADH7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AGT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AIF1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of AKR1C18 mRNA Pravastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] [Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein Pravastatin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17170375 PMID:17188708 PMID:18483861 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:16763553 PMID:27225895 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions decreases expression |
ISO |
Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA] |
CTD |
PMID:16763553 |
|
NCBI chr 8:77,640,234...77,719,488
Ensembl chr 8:77,640,222...77,719,489
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
affects expression |
EXP ISO |
Pravastatin affects the expression of ALDH1A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Aldoart2 |
aldolase 1 A retrogene 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ALDOART2 mRNA Pravastatin results in decreased expression of ALDOART2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:76,349,362...76,351,052
Ensembl chr 6:76,349,362...76,351,051
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of AMPD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:117,698,590...117,706,729
Ensembl chr 5:117,698,764...117,705,808
|
|
G |
Ank2 |
ankyrin 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANK2 mRNA Pravastatin results in decreased expression of ANK2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:231,224,643...231,522,655
Ensembl chr 2:231,226,949...231,648,122
|
|
G |
Anks6 |
ankyrin repeat and sterile alpha motif domain containing 6 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANKS6 mRNA Pravastatin results in decreased expression of ANKS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:62,642,974...62,684,387
Ensembl chr 5:62,640,645...62,683,964
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of APOA1 mRNA Pravastatin results in decreased expression of APOA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
Pravastatin results in increased expression of APP |
CTD |
PMID:19461118 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of ARG2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:102,311,097...102,338,406
Ensembl chr 6:102,311,116...102,338,520
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of ARHGAP11A mRNA Pravastatin affects the expression of ARHGAP11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:105,281,827...105,298,108
Ensembl chr 3:105,281,827...105,298,108
|
|
G |
Arntl2 |
aryl hydrocarbon receptor nuclear translocator-like 2 |
increases expression affects expression |
ISO EXP |
Pravastatin results in increased expression of ARNTL2 mRNA Pravastatin affects the expression of ARNTL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:181,103,774...181,158,415
Ensembl chr 4:181,103,774...181,214,994
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:8,732,907...8,745,445
Ensembl chr 2:8,732,932...8,743,069
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ATP4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:89,162,700...89,175,504
Ensembl chr 1:89,162,639...89,175,811
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ATP6V0D2 mRNA Pravastatin results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:33,843,591...33,892,446
Ensembl chr 5:33,843,519...33,892,462
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AXIN2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of BARD1 mRNA Pravastatin affects the expression of BARD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein |
CTD |
PMID:26875785 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein |
CTD |
PMID:26875785 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:12,403,385...12,409,103
Ensembl chr12:12,403,385...12,407,561
|
|
G |
Bmper |
BMP-binding endothelial regulator |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of BMPER mRNA Pravastatin results in increased expression of BMPER mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:24,369,916...24,615,484
Ensembl chr 8:24,369,916...24,615,479
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of BUB1B mRNA Pravastatin results in decreased expression of BUB1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:110,367,949...110,420,471
Ensembl chr 3:110,367,939...110,420,458
|
|
G |
C1qb |
complement C1q B chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C1QB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:155,246,444...155,251,995
Ensembl chr 5:155,246,447...155,252,003
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C1QC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
|
|
G |
C5ar1 |
complement C5a receptor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:78,186,777...78,195,132
Ensembl chr 1:78,186,776...78,195,328
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein] Pravastatin results in increased cleavage of CASP3 protein Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:18483861 PMID:20368269 PMID:26875785 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Pravastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl12 |
chemokine (C-C motif) ligand 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CCL12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:69,476,866...69,478,416
Ensembl chr10:69,476,775...69,478,462
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] |
CTD |
PMID:18323514 PMID:20884875 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CCL6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Cd209 |
CD209 molecule |
decreases expression |
EXP |
Pravastatin results in decreased expression of CD209 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:2,406,879...2,413,324
Ensembl chr12:2,406,879...2,413,324
|
|
G |
Cd209a |
CD209a antigen |
decreases expression |
ISO |
Pravastatin results in decreased expression of CD209 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:2,341,960...2,347,543
Ensembl chr12:2,341,960...2,347,543
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CD28 mRNA Pravastatin affects the expression of CD28 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:67,546,408...67,573,858
Ensembl chr 9:67,546,408...67,571,871
|
|
G |
Cd40 |
CD40 molecule |
affects expression |
EXP ISO |
Pravastatin affects the expression of CD40 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd7 |
Cd7 molecule |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:110,229,931...110,232,812
Ensembl chr10:110,229,922...110,232,843
|
|
G |
Cdc27 |
cell division cycle 27 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CDC27 mRNA Pravastatin results in increased expression of CDC27 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of CDC6 mRNA Pravastatin affects the expression of CDC6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of CDCA7L mRNA Pravastatin results in decreased expression of CDCA7L mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:145,739,570...145,785,607
Ensembl chr 6:145,740,035...145,785,606
|
|
G |
Cdhr5 |
cadherin-related family member 5 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CDHR5 mRNA Pravastatin results in increased expression of CDHR5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:214,255,118...214,263,848
Ensembl chr 1:214,255,110...214,263,581
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] |
CTD |
PMID:15625077 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CDS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:9,396,511...9,456,964
Ensembl chr14:9,396,512...9,456,990
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Pravastatin results in increased expression of CEBPD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:89,008,008...89,009,146
Ensembl chr11:89,008,008...89,009,146
|
|
G |
Cers6 |
ceramide synthase 6 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CERS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:55,094,240...55,338,370
Ensembl chr 3:55,094,637...55,338,445
|
|
G |
Cesl1 |
carboxylesterase-like 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CESL1 mRNA |
CTD |
PMID:27225895 |
|
Ensembl chr19:15,081,158...15,335,002
|
|
G |
Cip2a |
cellular inhibitor of PP2A |
decreases expression |
EXP |
Pravastatin results in decreased expression of CIP2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:54,373,794...54,404,704
Ensembl chr11:54,377,374...54,404,612
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CITED1 mRNA Pravastatin results in increased expression of CITED1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:72,128,996...72,133,692
Ensembl chr X:72,128,994...72,133,692
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CLCN6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:164,811,815...164,844,554
Ensembl chr 5:164,811,816...164,844,586
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CLEC4F mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:115,322,300...115,332,021
Ensembl chr 4:115,322,291...115,332,052
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CLSTN3 mRNA Pravastatin affects the expression of CLSTN3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130
|
|
G |
Cnn1 |
calponin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:23,113,083...23,121,748
Ensembl chr 8:23,113,048...23,121,761
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CPT1B mRNA Pravastatin affects the expression of CPT1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:130,395,211...130,404,731
Ensembl chr 7:130,395,194...130,405,347
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CPT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of CRAT mRNA Pravastatin affects the expression of CRAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:8,967,984...8,981,959
Ensembl chr 3:8,968,417...8,981,362
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CREB3L3 mRNA Pravastatin affects the expression of CREB3L3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:11,490,852...11,499,287
Ensembl chr 7:11,490,852...11,499,282
|
|
G |
Crp |
C-reactive protein |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CRP mRNA Pravastatin results in increased expression of CRP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSAD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSF1R mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSMD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:77,152,823...78,850,222
Ensembl chr16:78,539,489...78,850,222
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization multiple interactions |
EXP |
Pravastatin affects the localization of CTNNB1 protein [resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein |
CTD |
PMID:17188708 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CXCL2 mRNA Pravastatin results in increased expression of CXCL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYBA protein |
CTD |
PMID:17170375 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] |
CTD |
PMID:18483861 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CYP1B1 mRNA Pravastatin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects expression |
ISO |
Pravastatin affects the expression of CYP2B10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b21 |
cytochrome P450, family 2, subfamily b, polypeptide 21 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2B21 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:83,389,783...83,418,613
Ensembl chr 1:83,389,788...83,418,777
|
|
G |
Cyp2d1 |
cytochrome P450, family 2, subfamily d, polypeptide 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CYP2D10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:123,625,641...123,630,045
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:123,634,400...123,638,757
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2J4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
affects expression |
EXP |
Pravastatin affects the expression of CYP4A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:134,196,910...134,207,888
Ensembl chr 5:134,196,912...134,207,863
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:134,468,666...134,484,851
Ensembl chr 5:134,469,270...134,484,839
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DECR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:29,573,893...29,601,731
Ensembl chr 5:29,573,898...29,601,748
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DEPDC1B mRNA Pravastatin affects the expression of DEPDC1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:39,980,796...40,069,982
Ensembl chr 2:40,000,313...40,069,975
|
|
G |
Derl3 |
derlin 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DERL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:13,692,102...13,707,645
Ensembl chr20:13,704,314...13,706,205
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of DIO3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DLGAP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:118,277,046...119,159,807
Ensembl chr 9:118,586,179...119,158,196
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
affects farnesylation |
ISO |
Pravastatin affects the farnesylation of DNAJA1 protein |
CTD |
PMID:20884875 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Dnase2b |
deoxyribonuclease 2 beta |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of DNASE2B mRNA Pravastatin results in decreased expression of DNASE2B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:252,436,363...252,475,506
Ensembl chr 2:252,436,332...252,451,999
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:43,475,640...43,581,725
Ensembl chr15:43,477,629...43,542,939
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DTL mRNA Pravastatin affects the expression of DTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:110,219,276...110,257,345
Ensembl chr13:110,220,283...110,257,367
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ECH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EDN1 protein Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein |
CTD |
PMID:12105140 PMID:19812503 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression |
ISO EXP |
Pravastatin results in increased expression of EFHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:47,988...120,800
Ensembl chr 9:47,724...120,799
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of EHHADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:82,945,104...82,978,364
Ensembl chr11:82,945,104...82,978,364
|
|
G |
Enpp5 |
ectonucleotide pyrophosphatase/phosphodiesterase family member 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of ENPP5 mRNA Pravastatin results in decreased expression of ENPP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:19,469,276...19,476,684
Ensembl chr 9:19,469,706...19,476,646
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of ENTPD2 mRNA Pravastatin results in increased expression of ENTPD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:2,617,795...2,623,818
Ensembl chr 3:2,617,805...2,623,445
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EPHX2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Ephx4 |
epoxide hydrolase 4 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of EPHX4 mRNA Pravastatin affects the expression of EPHX4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:3,360,680...3,389,996
Ensembl chr14:3,360,712...3,389,943
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EVI2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:66,870,048...66,873,948
Ensembl chr10:66,870,067...66,873,948
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of F13A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:28,504,650...28,680,015
Ensembl chr17:28,504,623...28,680,362
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FABP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of FABP2 mRNA Pravastatin results in decreased expression of FABP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of FABP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FAR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:178,351,674...178,412,838
Ensembl chr 1:178,351,680...178,431,395
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
Pravastatin results in increased expression of FBN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:117,569,708...117,766,160
Ensembl chr 3:117,569,697...117,766,120
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
affects expression |
EXP |
Pravastatin affects the expression of FBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:372,554...389,918
Ensembl chr17:372,551...389,967
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects activity |
ISO |
Pravastatin affects the activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of FGD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:6,973,356...6,990,026
Ensembl chr20:6,973,398...6,990,023
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of FGF13 mRNA Pravastatin results in increased expression of FGF13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:142,053,648...142,589,274
Ensembl chr X:142,053,654...142,248,369
|
|
G |
Flacc1 |
flagellum associated containing coiled-coil domains 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FLACC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:65,665,663...65,693,822
Ensembl chr 9:65,665,664...65,693,822
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:3,427,890...3,438,418
Ensembl chr20:3,427,880...3,438,396
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of FOLR2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:166,915,045...166,933,377
Ensembl chr 1:166,915,045...166,919,302
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Pravastatin results in decreased expression of GCK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCLC mRNA Pravastatin results in decreased expression of GCLC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCNT2 mRNA Pravastatin results in decreased expression of GCNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein] |
CTD |
PMID:20884875 |
|
NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLDC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:248,295,140...248,377,122
Ensembl chr 1:248,297,331...248,377,093
|
|
G |
Gls2 |
glutaminase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLS2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:2,605,679...2,621,853
Ensembl chr 7:2,605,719...2,621,852
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of GPR85 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:40,377,705...40,387,147
Ensembl chr 4:40,381,685...40,385,349
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:71,621,777...71,626,096
Ensembl chr 4:71,621,729...71,626,107
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:27,589,840...27,628,921
Ensembl chr 6:27,589,657...27,629,175
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:27,555,408...27,589,539
Ensembl chr 6:27,555,412...27,582,995
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
EXP ISO |
Pravastatin results in increased expression of HAMP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 2:189,330,900...189,333,305
Ensembl chr 2:189,330,902...189,333,322
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance increases expression decreases activity affects expression |
ISO EXP |
HMGCR gene SNP results in decreased susceptibility to Pravastatin Pravastatin results in increased expression of HMGCR mRNA Pravastatin results in decreased activity of HMGCR protein Pravastatin affects the expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Pravastatin results in increased expression of HMGCS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:20368269 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hopx |
HOP homeobox |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HOPX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:33,354,803...33,362,547
Ensembl chr14:33,354,807...33,362,551
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HRG mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:81,621,274...81,639,938
Ensembl chr11:81,621,283...81,639,952
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of HSD17B7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:88,288,116...88,308,019
Ensembl chr13:88,288,046...88,307,988
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of HSDL2 mRNA Pravastatin results in increased expression of HSDL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of IL1B mRNA Pravastatin results in increased expression of IL1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein] Pravastatin results in decreased expression of IL6 protein |
CTD |
PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr 2:46,996,904...47,097,011
Ensembl chr 2:47,000,323...47,096,961
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb6 |
integrin subunit beta 6 |
affects expression |
ISO |
Pravastatin affects the expression of ITGB6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:46,652,624...46,775,362
Ensembl chr 3:46,652,623...46,726,958
|
|
G |
Kcns3 |
potassium voltage-gated channel, modifier subfamily S, member 3 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of KCNS3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:36,764,040...36,819,810
Ensembl chr 6:36,764,044...36,819,821
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KCTD12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:87,384,632...87,390,627
|
|
G |
Kif20a |
kinesin family member 20A |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20A mRNA Pravastatin results in decreased expression of KIF20A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:27,424,328...27,432,814
Ensembl chr18:27,424,328...27,432,814
|
|
G |
Kif20b |
kinesin family member 20B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20B mRNA Pravastatin results in decreased expression of KIF20B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:253,220,038...253,275,523
Ensembl chr 1:253,221,812...253,275,490
|
|
G |
Kif23 |
kinesin family member 23 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF23 mRNA Pravastatin results in decreased expression of KIF23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:66,866,043...66,893,241
Ensembl chr 8:66,866,082...66,893,196
|
|
G |
Kitlg |
KIT ligand |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of KITLG mRNA Pravastatin affects the expression of KITL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Klb |
klotho beta |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KLB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:44,529,523...44,614,093
|
|
G |
Krt23 |
keratin 23 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of KRT23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:87,391,623...87,407,634
Ensembl chr10:87,391,623...87,407,634
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity increases response to substance multiple interactions |
ISO |
Pravastatin results in increased activity of LDLR protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein |
CTD |
PMID:8593127 PMID:26875785 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lgals4 |
galectin 4 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of LGALS4 mRNA Pravastatin results in decreased expression of LGALS4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:87,019,598...87,027,720
Ensembl chr 1:87,019,975...87,027,691
|
|
G |
Lgi2 |
leucine-rich repeat LGI family, member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LGI2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:60,764,325...60,791,809
Ensembl chr14:60,764,409...60,796,116
|
|
G |
Lmna |
lamin A/C |
increases expression |
ISO |
Pravastatin results in increased expression of LMNA protein |
CTD |
PMID:20884875 |
|
NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
|
|
G |
LOC100910526 |
sulfotransferase 1C2-like |
decreases expression |
ISO |
Pravastatin results in decreased expression of SULT1C2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:4,820,678...4,834,271
Ensembl chr 9:4,807,717...4,834,335
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of LPL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrmda |
leucine rich melanocyte differentiation associated |
decreases expression |
ISO |
Pravastatin results in decreased expression of LRMDA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:1,269,869...2,346,246
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LSS mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LTBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:108,500,114...108,596,653
Ensembl chr 6:108,500,112...108,596,569
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of LY86 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:28,104,535...28,191,447
Ensembl chr17:28,104,589...28,191,436
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MAPT Pravastatin results in decreased expression of MAPT mRNA |
CTD |
PMID:19461118 PMID:27225895 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mastl |
microtubule associated serine/threonine kinase-like |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MASTL mRNA Pravastatin results in decreased expression of MASTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:89,839,562...89,875,855
Ensembl chr17:89,742,140...89,876,825
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
Pravastatin results in increased phosphorylation of MDM2 protein Pravastatin results in increased expression of MDM2 protein [Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein] |
CTD |
PMID:15625077 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Meiob |
meiosis specific with OB-fold |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of MEIOB mRNA Pravastatin results in increased expression of MEIOB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:14,174,645...14,206,026
Ensembl chr10:14,174,732...14,206,025
|
|
G |
Mgll |
monoglyceride lipase |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of MGLL mRNA Pravastatin affects the expression of MGLL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:120,671,436...120,773,458
Ensembl chr 4:120,671,489...120,771,088
|
|
G |
Miox |
myo-inositol oxygenase |
decreases expression |
ISO |
Pravastatin results in decreased expression of MIOX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:130,308,707...130,311,205
Ensembl chr 7:130,308,532...130,313,727
|
|
G |
Mis18a |
MIS18 kinetochore protein A |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of MIS18A mRNA Pravastatin results in decreased expression of MIS18A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:30,880,231...30,893,262
Ensembl chr11:30,879,887...30,893,310
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of MLYCD mRNA Pravastatin affects the expression of MLYCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:52,032,950...52,048,773
Ensembl chr19:52,032,886...52,048,753
|
|
G |
Mme |
membrane metallo-endopeptidase |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of MME mRNA Pravastatin results in decreased expression of MME mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:153,799,203...153,880,910
Ensembl chr 2:153,803,349...153,880,738
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases expression |
EXP |
Pravastatin results in decreased expression of MMP14 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity decreases expression |
EXP |
Pravastatin results in decreased activity of MMP2 protein Pravastatin results in decreased expression of MMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
affects response to substance |
ISO |
MMP3 promoter polymorphism affects the susceptibility to Pravastatin |
CTD |
PMID:8662692 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity decreases expression |
EXP |
Pravastatin results in decreased activity of MMP9 protein Pravastatin results in decreased expression of MMP9 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of MSS51 mRNA Pravastatin results in increased expression of MSS51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:4,240,203...4,252,072
Ensembl chr15:4,240,203...4,252,072
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Pravastatin results in increased phosphorylation of MTOR protein |
CTD |
PMID:15625077 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of MVD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of NFE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:144,872,739...144,880,092
Ensembl chr 7:144,872,747...144,880,092
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of NNMT mRNA Pravastatin results in decreased expression of NNMT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:52,918,437...52,938,172
Ensembl chr 8:52,925,175...52,937,972
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation |
EXP |
[Resveratrol co-treated with Pravastatin] results in increased phosphorylation of NOS3 protein; Pravastatin promotes the reaction [NOS3 protein binds to NOS3 protein]; Pravastatin promotes the reaction [olmesartan results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pravastatin results in increased activity of and results in increased phosphorylation of NOS3 protein Pravastatin results in increased phosphorylation of NOS3 protein |
CTD |
PMID:17170375 PMID:17188708 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP ISO |
Pravastatin results in increased expression of NSDHL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:152,933,118...152,964,399
Ensembl chr X:152,933,069...152,964,390
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Pravastatin results in increased expression of OLR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of ORC1 mRNA Pravastatin results in decreased expression of ORC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:128,186,651...128,212,901
Ensembl chr 5:128,190,708...128,210,445
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
increases expression |
EXP |
Pravastatin results in increased expression of PCDHB4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:30,398,113...30,400,695
Ensembl chr18:30,398,113...30,400,695
|
|
G |
Pcdhb8 |
protocadherin beta 8 |
increases expression |
ISO |
Pravastatin results in increased expression of PCDHB4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:30,435,119...30,437,458
Ensembl chr18:30,435,119...30,437,458
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PCSK9 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:126,031,368...126,053,726
Ensembl chr 5:126,031,368...126,053,726
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
ISO |
Pravastatin results in decreased expression of PCTP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:77,491,445...77,537,268
Ensembl chr10:77,491,454...77,512,032
|
|
G |
Pde4a |
phosphodiesterase 4A |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of PDE4A mRNA Pravastatin results in increased expression of PDE4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:22,189,533...22,234,036
Ensembl chr 8:22,189,600...22,233,748
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of PDK4 mRNA Pravastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEMT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:46,339,821...46,404,640
Ensembl chr10:46,339,821...46,404,642
|
|
G |
Pex11a |
peroxisomal biogenesis factor 11 alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEX11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:141,474,189...141,481,270
Ensembl chr 1:141,474,180...141,481,315
|
|
G |
Pf4 |
platelet factor 4 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PF4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Pla2r1 |
phospholipase A2 receptor 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PLA2R1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:46,488,963...46,621,873
Ensembl chr 3:46,488,186...46,621,873
|
|
G |
Plppr1 |
phospholipid phosphatase related 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of PLPPR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:67,852,817...67,985,310
Ensembl chr 5:67,852,180...68,139,199
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PMVK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:188,784,329...188,793,890
Ensembl chr 2:188,784,222...188,793,895
|
|
G |
Pnpla7 |
patatin-like phospholipase domain containing 7 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PNPLA7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:2,182,191...2,261,890
Ensembl chr 3:2,182,957...2,261,878
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of POLE2 mRNA Pravastatin results in decreased expression of POLE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:91,494,348...91,532,355
Ensembl chr 6:91,494,393...91,518,996
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions affects localization |
ISO EXP |
Pravastatin results in increased expression of PPARA protein Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] Pravastatin affects the localization of PPARA protein [[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:18812576 PMID:20368269 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol] |
CTD |
PMID:12044893 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppm1j |
protein phosphatase, Mg2+/Mn2+ dependent, 1J |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of PPM1J mRNA Pravastatin results in increased expression of PPM1J mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:207,263,307...207,268,601
Ensembl chr 2:207,262,934...207,268,609
|
|
G |
Prnd |
prion like protein doppel |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PRND mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:124,543,227...124,548,548
Ensembl chr 3:124,545,364...124,545,900
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Pravastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20368269 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
increases expression affects expression |
ISO EXP |
Pravastatin results in increased expression of PTPRN mRNA Pravastatin affects the expression of PTPRN mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:82,446,626...82,462,314
Ensembl chr 9:82,446,633...82,461,903
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of RDH11 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
|
|
G |
Reep1 |
receptor accessory protein 1 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of REEP1 mRNA Pravastatin results in increased expression of REEP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:99,618,622...99,735,329
Ensembl chr 4:99,618,622...99,735,319
|
|
G |
Retsat |
retinol saturase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of RETSAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:100,465,365...100,474,128
Ensembl chr 4:100,465,170...100,474,301
|
|
G |
RGD1560455 |
similar to RIKEN cDNA A630033H20 gene |
affects expression |
EXP |
Pravastatin affects the expression of RGD1560455 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:78,258,495...78,284,180
Ensembl chr X:78,259,409...78,284,180
|
|
G |
RGD1564308 |
similar to LOC495042 protein |
increases expression |
EXP |
Pravastatin results in increased expression of RGD1564308 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:49,485,022...49,509,756
Ensembl chr16:49,485,256...49,509,767
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of RGS16 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:71,163,411...71,185,147
Ensembl chr13:71,179,910...71,185,216
|
|
G |
Rnf186 |
ring finger protein 186 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of RNF186 mRNA Pravastatin affects the expression of RNF186 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:157,416,897...157,418,121
Ensembl chr 5:157,416,897...157,418,121
|
|
G |
Rragd |
Ras-related GTP binding D |
decreases expression |
ISO |
Pravastatin results in decreased expression of RRAGD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:48,224,994...48,260,691
Ensembl chr 5:48,224,994...48,260,685
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
EXP |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA |
CTD |
PMID:20368269 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of S100A4 mRNA Pravastatin results in increased expression of S100A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:189,997,278...189,999,587
Ensembl chr 2:189,997,129...189,999,604
|
|
G |
S100g |
S100 calcium binding protein G |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of S100G mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:33,442,820...33,445,714
Ensembl chr X:33,443,186...33,445,709
|
|
G |
Sat2 |
spermidine/spermine N1-acetyltransferase family member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SAT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:56,227,703...56,229,796
Ensembl chr10:56,227,692...56,229,850
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Pravastatin results in increased expression of SCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of SCD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:264,059,374...264,072,433
Ensembl chr 1:264,059,374...264,072,433
|
|
G |
Selp |
selectin P |
decreases expression |
ISO |
Pravastatin results in decreased expression of SELP protein |
CTD |
PMID:11189483 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Serpinb1a |
serpin family B member 1A |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SERPINB1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:32,903,089...32,911,498
Ensembl chr17:32,904,119...32,911,495
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
ISO |
Pravastatin results in increased expression of SFRP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:73,372,007...73,410,777
Ensembl chr16:73,372,007...73,410,777
|
|
G |
Shisa4 |
shisa family member 4 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of SHISA4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:52,193,989...52,197,205
Ensembl chr13:52,193,989...52,197,205
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slc13a3 |
solute carrier family 13 member 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SLC13A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:162,084,336...162,147,398
Ensembl chr 3:162,084,315...162,147,393
|
|
G |
Slc15a3 |
solute carrier family 15 member 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC15A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:226,896,387...226,912,644
Ensembl chr 1:226,897,625...226,912,708
|
|
G |
Slc16a5 |
solute carrier family 16 member 5 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of SLC16A5 mRNA Pravastatin affects the expression of SLC16A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:104,019,888...104,035,735
Ensembl chr10:104,019,888...104,034,595
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:43,473,048...43,504,645
|
|
G |
Slc17a3 |
solute carrier family 17 member 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC17A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:43,518,760...43,545,160
Ensembl chr17:43,518,655...43,543,185
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of SLC22A5 mRNA Pravastatin results in decreased expression of SLC22A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:39,201,101...39,228,090
Ensembl chr10:39,201,107...39,323,853
|
|
G |
Slc23a1 |
solute carrier family 23 member 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC23A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:28,413,910...28,428,133
Ensembl chr18:28,414,009...28,428,117
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SLC25A20 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:117,455,308...117,476,762
Ensembl chr 8:117,455,262...117,476,734
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
affects expression |
EXP |
Pravastatin affects the expression of SLC25A34 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:160,175,206...160,179,978
Ensembl chr 5:160,176,124...160,179,978
|
|
G |
Slc25a42 |
solute carrier family 25, member 42 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC25A42 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:20,962,144...21,000,191
Ensembl chr16:20,962,227...20,985,225
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:119,014,620...119,052,531
Ensembl chr 3:119,014,620...119,052,531
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC2A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Slc34a2 |
solute carrier family 34 member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:60,257,211...60,276,516
Ensembl chr14:60,256,712...60,276,794
|
|
G |
Slc9b2 |
solute carrier family 9 member B2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of SLC9B2 mRNA Pravastatin results in increased expression of SLC9B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:240,485,254...240,519,166
Ensembl chr 2:240,495,371...240,519,141
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects transport decreases expression |
ISO EXP |
SLCO1A4 protein affects the transport of Pravastatin Pravastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:19833843 PMID:24909372 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Slco1a5 |
solute carrier organic anion transporter family, member 1A5 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of SLCO1A5 mRNA Pravastatin results in decreased expression of SLCO1A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:176,445,856...176,528,117
Ensembl chr 4:176,445,858...176,528,110
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:175,838,994...175,857,985
Ensembl chr 3:175,838,994...175,857,983
|
|
G |
Smim3 |
small integral membrane protein 3 |
increases expression |
ISO |
Pravastatin results in increased expression of SMIM3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:55,744,809...55,797,186
Ensembl chr18:55,744,810...55,771,730
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein |
CTD |
PMID:26875785 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Pravastatin results in increased expression of SOCS3 protein |
CTD |
PMID:19330073 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Spag5 |
sperm associated antigen 5 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of SPAG5 mRNA Pravastatin results in decreased expression of SPAG5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:65,552,780...65,585,773
Ensembl chr10:65,566,171...65,585,760 Ensembl chr10:65,566,171...65,585,760
|
|
G |
Spic |
Spi-C transcription factor |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of SPIC mRNA Pravastatin results in increased expression of SPIC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:29,225,721...29,233,452
Ensembl chr 7:29,225,727...29,233,392
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:25,279,635...25,315,501
Ensembl chr 6:25,279,626...25,315,511
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ST8SIA3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:59,748,766...59,755,257
Ensembl chr18:59,748,444...59,755,226
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of STARD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
Pravastatin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:19330073 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein |
CTD |
PMID:26875785 |
|
NCBI chr12:24,682,050...24,710,002
Ensembl chr12:24,682,041...24,710,019
|
|
G |
Sult1c2a |
sulfotransferase family, cytosolic, 1C, member 2a |
affects expression |
EXP |
Pravastatin affects the expression of SULT1C2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:4,152,588...4,168,355
Ensembl chr 9:4,152,589...4,168,221
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Tex12 |
testis expressed 12 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of TEX12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:54,991,501...54,999,454
Ensembl chr 8:54,992,841...54,994,871
|
|
G |
Thbd |
thrombomodulin |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of THBD mRNA Pravastatin results in increased expression of THBD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:142,748,673...142,752,325
Ensembl chr 3:142,748,674...142,752,325
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TIMP1 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TIMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
|
|
G |
Tlcd4 |
TLC domain containing 4 |
decreases expression |
ISO |
Pravastatin results in decreased expression of TLCD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:224,768,034...224,843,198
Ensembl chr 2:224,772,893...224,802,997
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:221,426,017...221,430,340
Ensembl chr 1:221,425,987...221,431,713
|
|
G |
Tmem139 |
transmembrane protein 139 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of TMEM139 mRNA Pravastatin results in decreased expression of TMEM139 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:71,648,705...71,651,861
Ensembl chr 4:71,650,575...71,651,438
|
|
G |
Tmem164 |
transmembrane protein 164 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of TMEM164 mRNA Pravastatin results in increased expression of TMEM164 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:113,947,355...114,110,064
Ensembl chr X:113,948,654...114,110,062
|
|
G |
Tmem205 |
transmembrane protein 205 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of TMEM205 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:22,932,175...22,937,953
Ensembl chr 8:22,932,175...22,937,909
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin results in increased expression of TNF mRNA |
CTD |
PMID:17729120 PMID:18323514 PMID:27225895 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf18 |
TNF superfamily member 18 |
affects expression |
ISO EXP |
Pravastatin affects the expression of TNFSF18 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:79,378,412...79,388,687
Ensembl chr13:79,378,733...79,388,498
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
ISO |
Pravastatin results in increased expression of TNNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:52,662,974...52,680,992
Ensembl chr13:52,662,996...52,680,990
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] |
CTD |
PMID:15625077 PMID:20650967 PMID:20884875 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tspan13 |
tetraspanin 13 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TSPAN13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:55,497,659...55,524,415
Ensembl chr 6:55,497,658...55,524,436
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:140,637,287...140,640,953
Ensembl chr 7:140,637,287...140,640,953
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
G |
Uroc1 |
urocanate hydratase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of UROC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:122,244,744...122,276,357
Ensembl chr 4:122,244,711...122,276,361
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein |
CTD |
PMID:26875785 |
|
NCBI chr10:55,675,171...55,679,405
Ensembl chr10:55,675,575...55,679,450
|
|
G |
Vnn1 |
vanin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of VNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:22,614,832...22,625,134
Ensembl chr 1:22,614,783...22,625,204
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ZC3H12A mRNA Pravastatin results in decreased expression of ZC3H12A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:143,111,342...143,120,131
Ensembl chr 5:143,111,074...143,120,165
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
EXP |
Simvastatin results in decreased expression of A2M mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:154,309,426...154,359,138
Ensembl chr 4:154,309,426...154,359,137
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein |
CTD |
PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 PMID:22120639 PMID:25055962 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression decreases activity |
ISO EXP |
Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Simvastatin results in decreased expression of ABCB11 mRNA Simvastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases transport decreases activity affects response to substance |
ISO |
ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] ABCB1 protein results in increased transport of Simvastatin Simvastatin analog results in decreased activity of ABCB1 protein ABCB1 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of ABCB4 mRNA Simvastatin results in decreased expression of ABCB4 mRNA |
CTD |
PMID:21241519 PMID:27765674 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions decreases expression affects response to substance decreases activity |
EXP ISO |
ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Simvastatin results in decreased expression of ABCC2 mRNA ABCC2 polymorphism affects the susceptibility to Simvastatin Simvastatin analog results in decreased activity of ABCC2 protein |
CTD |
PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases nitrosation |
ISO |
artemisinine inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein] |
CTD |
PMID:18463201 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19383813 PMID:22120639 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Simvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:21241519 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of ACAA2 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:70,733,872...70,762,395
Ensembl chr18:70,733,872...70,762,395
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases expression |
EXP |
Simvastatin results in increased expression of ACACB mRNA |
CTD |
PMID:12056585 |
|
NCBI chr12:48,127,149...48,238,969
Ensembl chr12:48,127,149...48,238,887
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of ACTA2 protein Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA] |
CTD |
PMID:15677772 PMID:15855201 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Simvastatin results in increased expression of ACTB mRNA |
CTD |
PMID:25055962 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Actn4 |
actinin alpha 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ACTN4 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 1:87,078,012...87,147,347
Ensembl chr 1:87,078,020...87,147,333
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO EXP |
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein] carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:17641834 PMID:29071762 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein |
CTD |
PMID:19262002 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of AFP mRNA |
CTD |
PMID:10365819 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein] Simvastatin results in decreased expression of AGER protein |
CTD |
PMID:17038636 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO EXP |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA] Simvastatin results in decreased expression of AGT mRNA |
CTD |
PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 PMID:22306966 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
Simvastatin results in decreased expression of AGTR1 mRNA |
CTD |
PMID:17513949 PMID:18475152 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:65,110,706...65,143,930
Ensembl chr 4:65,110,746...65,143,941
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression decreases phosphorylation increases phosphorylation multiple interactions decreases activity |
ISO EXP |
Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein Simvastatin results in decreased phosphorylation of AKT1 protein Simvastatin results in increased phosphorylation of AKT1 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein] Simvastatin results in decreased activity of AKT1 protein Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 PMID:18047562 PMID:19299917 PMID:20060890 PMID:20464445 PMID:20562903 PMID:20594940 PMID:21059805 PMID:22082490 PMID:22144680 PMID:25412314 PMID:27734117 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Alk |
ALK receptor tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
Simvastatin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:17183729 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
increases expression |
ISO |
Simvastatin results in increased expression of ALPI mRNA |
CTD |
PMID:14973129 |
|
NCBI chr 9:94,197,616...94,201,910
Ensembl chr 9:94,197,618...94,201,084
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression multiple interactions affects expression |
ISO |
Simvastatin results in increased expression of ALPL mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA] |
CTD |
PMID:20417880 PMID:28975700 |
|
NCBI chr 5:156,086,496...156,141,513
Ensembl chr 5:156,086,497...156,141,537
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
EXP |
Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein |
CTD |
PMID:18544044 |
|
NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein] |
CTD |
PMID:20821229 |
|
NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:117,698,590...117,706,729
Ensembl chr 5:117,698,764...117,705,808
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
increases expression |
EXP |
Simvastatin results in increased expression of ANKRA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:82,407,601...82,418,229
Ensembl chr X:82,407,598...82,418,425
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
Simvastatin results in increased expression of ANPEP mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 1:141,561,364...141,604,249
Ensembl chr 1:141,561,334...141,604,273
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ANXA1 protein |
CTD |
PMID:14973129 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ANXA3 mRNA Simvastatin results in decreased expression of ANXA3 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr14:14,371,921...14,426,503
Ensembl chr14:14,364,008...14,426,437
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
decreases expression |
EXP |
Simvastatin results in decreased expression of APMAP protein |
CTD |
PMID:20217863 |
|
NCBI chr 3:146,376,828...146,407,259
Ensembl chr 3:146,376,828...146,407,252
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression increases expression |
ISO EXP |
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein] Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA] |
CTD |
PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 PMID:18420099 PMID:18540024 PMID:20152243 PMID:21241519 PMID:25055962 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:89,596,872...89,598,805
Ensembl chr13:89,597,138...89,598,802
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions decreases expression increases expression |
ISO EXP |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein] Simvastatin results in increased expression of APOA4 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962 |
|
NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases expression decreases secretion affects response to substance |
ISO EXP |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] Simvastatin results in decreased expression of APOB protein Simvastatin results in decreased secretion of APOB protein Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein] APOB polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 PMID:11728391 PMID:12633795 PMID:12901521 PMID:15184351 PMID:18471454 PMID:18702965 PMID:20413733 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOC1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:80,606,638...80,609,921
Ensembl chr 1:80,606,638...80,609,921
|
|
G |
Apoc3 |
apolipoprotein C3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOC3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:50,529,318...50,531,498
Ensembl chr 8:50,529,318...50,531,498
|
|
G |
Apoe |
apolipoprotein E |
decreases expression affects response to substance multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein APOE polymorphism affects the susceptibility to Simvastatin Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein] APOE affects the susceptibility to Simvastatin |
CTD |
PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 PMID:18270459 PMID:19461118 PMID:25055962 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOF mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:2,689,501...2,690,938
Ensembl chr 7:2,689,501...2,690,936
|
|
G |
Apom |
apolipoprotein M |
decreases expression increases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of APOM mRNA Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein TO-901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; TO-901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] |
CTD |
PMID:21729290 PMID:22160096 |
|
NCBI chr20:5,120,473...5,123,073
Ensembl chr20:5,120,474...5,123,073
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases activity |
ISO EXP |
oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein] |
CTD |
PMID:17241114 PMID:28734741 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:225,552,075...225,613,349
Ensembl chr 2:225,552,148...225,613,359
|
|
G |
Arhgap4 |
Rho GTPase activating protein 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGAP4 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr X:156,873,094...156,888,762
Ensembl chr X:156,873,849...156,888,761
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ASS1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:10,327,411...10,375,847
Ensembl chr 3:10,327,414...10,375,826
|
|
G |
Atf2 |
activating transcription factor 2 |
increases phosphorylation |
EXP |
Simvastatin results in increased phosphorylation of ATF2 protein |
CTD |
PMID:15488325 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Simvastatin results in increased expression of ATF3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein |
CTD |
PMID:18807172 |
|
NCBI chr13:89,053,457...89,242,531
Ensembl chr13:89,055,983...89,242,443
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein |
CTD |
PMID:20499237 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein |
CTD |
PMID:15916736 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp6v1e1 |
ATPase H+ transporting V1 subunit E1 |
increases expression |
ISO |
Simvastatin results in increased expression of ATP6V1E1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:153,351,434...153,373,558
Ensembl chr 4:153,351,421...153,373,649
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Simvastatin results in decreased expression of AURKA mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Axin2 |
axin 2 |
affects expression |
EXP |
Simvastatin affects the expression of AXIN2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
ISO |
Simvastatin results in decreased expression of AXL mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:12438947 PMID:27734117 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases expression |
ISO EXP |
Simvastatin affects the localization of BAX protein Simvastatin results in increased expression of BAX protein Simvastatin results in increased expression of BAX mRNA Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein |
CTD |
PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression affects localization |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein] Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein Simvastatin affects the localization of BBC3 protein |
CTD |
PMID:17428261 PMID:20045437 PMID:21199873 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased expression of BCL2 protein Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein |
CTD |
PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 PMID:20369390 PMID:21729534 PMID:25300705 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] Simvastatin results in decreased expression of BCL2L1 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:20060890 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of BDNF Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA] |
CTD |
PMID:18047562 PMID:20851742 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions increases secretion |
ISO EXP |
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA] [Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP Simvastatin results in increased secretion of BGLAP protein |
CTD |
PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 PMID:19216230 PMID:19249597 PMID:19292885 PMID:20381859 PMID:20417880 PMID:20564244 PMID:21431270 PMID:22058016 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr12:12,403,385...12,409,103
Ensembl chr12:12,403,385...12,407,561
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Simvastatin results in decreased expression of BIRC2 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19343037 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:17277159 PMID:19343037 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein] Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17277159 PMID:20464445 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
increases expression |
EXP |
Simvastatin results in increased expression of BMP1 mRNA |
CTD |
PMID:12963647 |
|
NCBI chr15:52,166,401...52,210,786
Ensembl chr15:52,166,401...52,210,746
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases secretion increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased secretion of BMP2 protein Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA] Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] |
CTD |
PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 PMID:18310456 PMID:18628692 PMID:19292885 PMID:19912653 PMID:20024970 PMID:20381859 PMID:20417880 PMID:20687301 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
affects expression increases stability increases expression |
ISO |
Simvastatin affects the expression of BMPR2 mRNA Simvastatin results in increased stability of BMPR2 mRNA Simvastatin results in increased expression of BMPR2 protein |
CTD |
PMID:16297860 |
|
NCBI chr 9:66,568,074...66,683,019
Ensembl chr 9:66,568,074...66,676,494
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Simvastatin results in increased expression of BNIP3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
C5ar1 |
complement C5a receptor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:78,186,777...78,195,132
Ensembl chr 1:78,186,776...78,195,328
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein] Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein |
CTD |
PMID:19791473 |
|
NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein] Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein |
CTD |
PMID:19791473 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 5:29,538,380...29,562,774
Ensembl chr 5:29,538,380...29,562,773
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CALB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr19:41,482,743...41,509,617
Ensembl chr19:41,482,728...41,509,658
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein |
CTD |
PMID:14630613 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Calml3 |
calmodulin-like 3 |
increases expression |
ISO |
Simvastatin results in increased expression of CALML3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:70,070,458...70,073,697
Ensembl chr17:70,072,156...70,073,530
|
|
G |
Capn1 |
calpain 1 |
increases expression |
ISO |
Simvastatin results in increased expression of CAPN1 mRNA |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Capza1 |
capping actin protein of muscle Z-line subunit alpha 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CAPZA1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 2:207,305,748...207,350,812
Ensembl chr 2:207,305,752...207,350,812
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CAPZA2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 4:44,936,290...44,972,270
Ensembl chr 4:44,936,290...44,972,267
|
|
G |
Casp1 |
caspase 1 |
decreases activity multiple interactions |
EXP |
Simvastatin results in decreased activity of CASP1 protein Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein] |
CTD |
PMID:16054375 PMID:30408459 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein |
CTD |
PMID:19253821 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases activity increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein Simvastatin results in increased cleavage of CASP3 protein Simvastatin results in decreased activity of CASP3 protein Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein] [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein] |
CTD |
PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 PMID:15949312 PMID:16054375 PMID:16325779 PMID:16470222 PMID:16698853 PMID:17241114 PMID:17428261 PMID:17928392 PMID:18004065 PMID:18031796 PMID:18521906 PMID:18826357 PMID:19253821 PMID:19343037 PMID:20045437 PMID:20403180 PMID:20427495 PMID:20464445 PMID:20883752 PMID:21651924 PMID:21729534 PMID:21968084 PMID:22022327 PMID:25300705 PMID:26773838 PMID:27734117 PMID:29071762 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein |
CTD |
PMID:19253821 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:19253821 PMID:20045437 PMID:20427495 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions increases cleavage |
ISO |
Simvastatin results in increased activity of CASP8 protein Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein Simvastatin results in increased cleavage of CASP8 protein Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein] |
CTD |
PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity decreases activity increases cleavage |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 PMID:20045437 PMID:21910007 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
decreases expression multiple interactions increases activity |
ISO EXP |
Simvastatin results in decreased expression of CAT mRNA carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein] Simvastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA] Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein] Simvastatin results in decreased expression of CAV1 protein Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:16698853 PMID:18224302 PMID:19816600 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein] |
CTD |
PMID:16698853 |
|
NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:18224302 |
|
NCBI chr20:10,361,987...10,386,663
Ensembl chr20:10,361,988...10,386,751
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression affects expression decreases response to substance |
ISO EXP |
[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein Simvastatin affects the expression of CCL2 mRNA Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein Simvastatin results in decreased susceptibility to CCL2 protein |
CTD |
PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 PMID:15855201 PMID:16321392 PMID:16414398 PMID:16443229 PMID:16781696 PMID:17449418 PMID:18309148 PMID:19225232 PMID:19262002 PMID:21268089 PMID:22305382 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CCL20 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA] Simvastatin results in decreased expression of CCL3 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 protein Simvastatin results in decreased expression of CCL5 mRNA |
CTD |
PMID:17112859 PMID:17183729 PMID:17449418 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA] Simvastatin results in decreased expression of CCN1 mRNA |
CTD |
PMID:17428261 PMID:20191585 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 PMID:19659652 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CCNA2 mRNA Simvastatin results in decreased expression of CCNA2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein] |
CTD |
PMID:17428261 PMID:26577051 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein |
CTD |
PMID:17277159 PMID:17428261 PMID:20878096 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions decreases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein] |
CTD |
PMID:26577051 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA] Simvastatin results in decreased expression of CCR1 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr 8:132,996,646...133,002,201
Ensembl chr 8:132,996,649...133,002,201
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions decreases expression |
ISO EXP |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA] Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein |
CTD |
PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418 |
|
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr 8:122,530,152...122,535,959
Ensembl chr 8:122,530,624...122,532,070
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA] Simvastatin results in decreased expression of CCR5 protein Simvastatin results in decreased expression of CCR5 mRNA |
CTD |
PMID:16321392 PMID:17112859 PMID:17449418 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD14 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD151 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:214,446,659...214,450,668
Ensembl chr 1:214,009,784...214,013,765 Ensembl chr 1:214,009,784...214,013,765
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Simvastatin results in increased expression of CD24 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr20:48,335,540...48,340,847
Ensembl chr20:48,335,540...48,340,846
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD27 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
|
|
G |
Cd2ap |
CD2-associated protein |
increases expression |
ISO |
Simvastatin results in increased expression of CD2AP mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 9:20,794,680...20,858,438
Ensembl chr 9:20,765,296...20,858,504
|
|
G |
Cd40 |
CD40 molecule |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CD40 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]] |
CTD |
PMID:16387846 PMID:17169357 PMID:17507688 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression multiple interactions increases expression |
ISO |
Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA] Simvastatin results in increased expression of CD40LG protein |
CTD |
PMID:17169357 PMID:18269829 PMID:21330348 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter] Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd80 |
Cd80 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD80 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdc25b |
cell division cycle 25B |
affects expression |
ISO |
Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein |
CTD |
PMID:19110722 |
|
NCBI chr 3:123,731,539...123,741,696
Ensembl chr 3:123,731,539...123,741,339
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CDC42 protein |
CTD |
PMID:17169357 |
|
NCBI chr 5:155,690,267...155,728,385
Ensembl chr 5:155,691,390...155,728,300
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC45 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:86,328,785...86,354,099
Ensembl chr11:86,329,012...86,358,453
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
EXP |
Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein |
CTD |
PMID:19109527 |
|
NCBI chr19:1,025,122...1,074,333
Ensembl chr19:1,023,683...1,074,365
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein] |
CTD |
PMID:17428261 PMID:20878096 PMID:26577051 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression decreases activity |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in decreased expression of CDK2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein] Simvastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression decreases activity |
ISO EXP |
Simvastatin results in decreased expression of CDK4 protein Simvastatin results in decreased activity of CDK4 protein |
CTD |
PMID:18804536 PMID:20878096 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
ISO |
Simvastatin results in increased expression of CDK5 |
CTD |
PMID:19461118 |
|
NCBI chr 4:7,282,945...7,287,427
Ensembl chr 4:7,282,948...7,288,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 PMID:18804536 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 PMID:20878096 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN1C mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
EXP |
Simvastatin results in increased expression of CDKN2A protein |
CTD |
PMID:18804536 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein |
CTD |
PMID:20878096 |
|
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr19:55,381,565...55,386,511
Ensembl chr19:55,381,565...55,386,511
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr 6:1,516,804...1,534,488
Ensembl chr 6:1,516,804...1,534,488
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form |
CTD |
PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr 3:103,966,451...104,018,815
Ensembl chr 3:103,966,451...104,018,861
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions increases expression increases phosphorylation |
ISO |
artemisinine inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein] Simvastatin results in increased expression of CHUK mRNA |
CTD |
PMID:18463201 PMID:19262002 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein] |
CTD |
PMID:11219190 |
|
NCBI chr10:5,212,621...5,260,641
Ensembl chr10:5,213,350...5,260,608
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions increases secretion decreases expression |
ISO EXP |
[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein Simvastatin results in increased secretion of CKM protein carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein] Simvastatin results in decreased expression of CKM protein |
CTD |
PMID:8611662 PMID:19252767 PMID:29071762 |
|
NCBI chr 1:80,321,507...80,331,841
Ensembl chr 1:80,321,585...80,331,841
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein] Simvastatin results in decreased expression of CLCN3 protein |
CTD |
PMID:20644009 |
|
NCBI chr16:32,448,821...32,520,649
Ensembl chr16:32,449,116...32,519,148
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL11A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL12A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 8:87,042,820...87,150,701
Ensembl chr 8:87,040,799...87,158,368
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
decreases response to substance |
ISO |
COL13A1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr20:31,456,502...31,598,360
Ensembl chr20:31,456,852...31,598,118
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression decreases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] Simvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 PMID:20417880 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions increases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of COL3A1 mRNA Simvastatin results in decreased expression of COL3A1 mRNA |
CTD |
PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Simvastatin results in decreased expression of COL4A1 mRNA |
CTD |
PMID:10412775 |
|
NCBI chr16:83,522,162...83,632,153
Ensembl chr16:83,522,162...83,632,153
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL5A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 3:6,430,180...6,581,010
Ensembl chr 3:6,430,201...6,578,882
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL6A2 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL7A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:117,694,441...117,726,844
Ensembl chr 8:117,694,605...117,726,844
|
|
G |
Coro1a |
coronin 1A |
decreases expression |
EXP |
Simvastatin results in decreased expression of CORO1A protein |
CTD |
PMID:20217863 |
|
NCBI chr 1:198,123,883...198,128,890
Ensembl chr 1:198,123,884...198,128,857
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crp |
C-reactive protein |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CRP protein [Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] |
CTD |
PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 PMID:20152243 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
ISO |
Simvastatin results in increased expression of CSPG4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 8:61,532,465...61,567,510
Ensembl chr 8:61,532,465...61,567,510
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 1:199,162,319...199,168,296
Ensembl chr 1:199,163,086...199,168,296
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTLA4 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 9:67,699,397...67,706,068
Ensembl chr 9:67,699,379...67,706,065
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:73,561,249...73,621,070
Ensembl chr 5:73,561,450...73,621,070
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO EXP |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein] Simvastatin results in increased expression of CTNNB1 protein Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] |
CTD |
PMID:18004065 PMID:22058016 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Simvastatin results in increased expression of CTSL mRNA |
CTD |
PMID:19001041 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein] |
CTD |
PMID:20835264 |
|
NCBI chr 2:197,655,780...197,679,768
Ensembl chr 2:197,655,786...197,679,458
|
|
G |
Cttn |
cortactin |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of CTTN protein Simvastatin affects the reaction [F2 affects the localization of CTTN protein] |
CTD |
PMID:14630613 |
|
NCBI chr 1:217,602,698...217,638,196 NCBI chr 1:215,255,385...215,290,882
Ensembl chr 1:217,602,698...217,638,152 Ensembl chr 1:217,602,698...217,638,152
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:18359719 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein] Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein |
CTD |
PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
Simvastatin results in increased expression of CXCL12 |
CTD |
PMID:19591934 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCL16 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr10:57,060,005...57,064,600
Ensembl chr10:57,060,007...57,064,600
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCR2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:81,427,275...81,435,065
Ensembl chr 9:81,427,730...81,434,102
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression increases expression |
EXP |
Simvastatin results in decreased expression of CXCR4 mRNA Simvastatin results in increased expression of CXCR4 |
CTD |
PMID:16414398 PMID:19591934 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
affects response to substance |
ISO |
CYBA gene SNP affects the susceptibility to Simvastatin |
CTD |
PMID:15936011 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein] |
CTD |
PMID:30513525 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of CYP17A1 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:21918126 PMID:24524197 PMID:25055962 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Simvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:11753271 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CYP39A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 9:19,804,079...19,880,346
Ensembl chr 9:19,804,079...19,880,346
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects response to substance affects metabolic processing decreases activity multiple interactions increases expression decreases expression increases metabolic processing |
ISO EXP |
CYP3A4 polymorphism affects the susceptibility to Simvastatin CYP3A4 protein affects the metabolism of Simvastatin Simvastatin results in decreased activity of CYP3A4 protein [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; telaprevir inhibits the reaction [CYP3A4 protein results in increased metabolism of Simvastatin] Simvastatin results in increased expression of CYP3A4 mRNA Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] Simvastatin results in decreased expression of CYP3A4 mRNA; Simvastatin results in decreased expression of CYP3A4 protein |
CTD |
PMID:12505310 PMID:15650881 PMID:16011971 PMID:17041008 PMID:19802823 PMID:24204015 PMID:24927617 PMID:30086269 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance |
ISO |
CYP3A5 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:17192506 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CYP46A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:132,242,328...132,273,788
Ensembl chr 6:132,242,328...132,273,787
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Simvastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Dbf4 |
DBF4 zinc finger |
decreases expression |
ISO |
Simvastatin results in decreased expression of DBF4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:22,898,527...22,914,091
Ensembl chr 4:22,898,527...22,914,177
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 1:101,687,896...101,692,845
Ensembl chr 1:101,687,855...101,692,846
|
|
G |
Dcx |
doublecortin |
increases expression |
EXP |
Simvastatin results in increased expression of DCX |
CTD |
PMID:18544044 |
|
NCBI chr X:115,098,675...115,175,515
Ensembl chr X:115,098,675...115,175,299
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of DDAH1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:251,634,368...251,766,009
Ensembl chr 2:251,634,431...251,766,014
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression increases activity |
EXP |
Simvastatin results in increased expression of DGAT1 mRNA Simvastatin results in increased activity of DGAT1 protein |
CTD |
PMID:12056585 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO EXP |
Simvastatin results in increased expression of DHCR24 Simvastatin results in increased expression of DHCR24 mRNA Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein |
CTD |
PMID:21987590 PMID:25055962 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects response to substance affects expression multiple interactions |
ISO EXP |
DHCR7 mutant form affects the susceptibility to Simvastatin Simvastatin affects the expression of DHCR7 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol] Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] |
CTD |
PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of DIABLO protein DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:20045437 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] |
CTD |
PMID:22058016 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
increases expression |
EXP |
Simvastatin results in increased expression of DLL4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 3:111,135,011...111,146,746
Ensembl chr 3:111,135,021...111,145,986
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization increases expression |
ISO |
Simvastatin affects the localization of DNM1L protein Simvastatin results in increased expression of DNM1L protein |
CTD |
PMID:20045437 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions increases expression |
EXP |
SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein] Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein |
CTD |
PMID:15711596 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
increases expression |
EXP |
Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein |
CTD |
PMID:15711596 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dspp |
dentin sialophosphoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of DSPP mRNA |
CTD |
PMID:19249597 |
|
NCBI chr14:6,926,972...6,933,079
Ensembl chr14:6,926,976...6,933,070
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein |
CTD |
PMID:21080865 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of E2F1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr11:66,878,658...66,923,092
Ensembl chr11:66,878,658...66,923,092
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased secretion of EDN1 protein Simvastatin results in decreased expression of EDN1 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA] |
CTD |
PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 PMID:21844074 PMID:22022327 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA] |
CTD |
PMID:19505368 PMID:22022327 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20359552 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of EGR1 protein |
CTD |
PMID:12818400 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of EIF4EBP1 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22144680 PMID:27734117 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ENO1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr 1:259,692,020...259,818,922
Ensembl chr 1:259,739,955...259,819,494
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
|
|
G |
Epha8 |
Eph receptor A8 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 5:155,293,731...155,321,016
Ensembl chr 5:155,295,314...155,316,495
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
|
|
G |
F2 |
coagulation factor II |
multiple interactions decreases activity |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 PMID:14630613 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases activity decreases expression affects response to substance increases expression |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] Simvastatin results in decreased activity of F3 protein F3 polymorphism affects the susceptibility to Simvastatin Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein |
CTD |
PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 PMID:17513194 PMID:18031796 PMID:18841289 PMID:19027114 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO EXP |
Simvastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 PMID:12056585 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of FBXO32 mRNA IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA] |
CTD |
PMID:19001041 PMID:25300705 PMID:27734117 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression multiple interactions increases activity |
EXP ISO |
Simvastatin results in increased expression of FDFT1 protein Simvastatin results in increased expression of FDFT1 mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA] Simvastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 PMID:12518039 PMID:23386644 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of FDPS mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA] |
CTD |
PMID:23386644 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of FGF2 |
CTD |
PMID:20381859 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
decreases expression |
EXP |
Simvastatin results in decreased expression of FKBP1A mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:147,042,944...147,062,725
Ensembl chr 3:147,042,944...147,062,724
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
increases expression |
ISO |
Simvastatin results in increased expression of FKBP4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:161,748,993...161,757,447
Ensembl chr 4:161,748,993...161,757,447
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:3,427,890...3,438,418
Ensembl chr20:3,427,880...3,438,396
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions increases expression |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein] Simvastatin results in increased expression of FLT1 mRNA |
CTD |
PMID:19109527 PMID:20821229 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of FN1 mRNA Simvastatin results in increased expression of FN1 mRNA |
CTD |
PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression decreases localization |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA] Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA] FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein] Simvastatin results in decreased localization of FOS protein |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Simvastatin results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 6:25,598,936...25,616,995
Ensembl chr 6:25,598,936...25,616,995
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization decreases localization multiple interactions increases phosphorylation decreases phosphorylation |
EXP ISO |
Simvastatin affects the localization of FOXO1 protein Simvastatin results in decreased localization of FOXO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein] Simvastatin results in increased phosphorylation of FOXO1 protein Simvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:12438947 PMID:18826357 PMID:19001041 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions affects localization decreases phosphorylation decreases expression increases phosphorylation |
ISO EXP |
Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein] Simvastatin results in decreased phosphorylation of FOXO3 protein Simvastatin results in decreased expression of FOXO3 protein |
CTD |
PMID:19001041 PMID:20883752 PMID:27734117 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression decreases expression affects methylation multiple interactions |
ISO EXP |
Simvastatin results in increased expression of FOXP3 Simvastatin results in decreased expression of FOXP3 mRNA Simvastatin affects the methylation of FOXP3 promoter IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 PMID:20491794 PMID:22305382 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Fzd2 |
frizzled class receptor 2 |
increases expression |
EXP |
Simvastatin results in increased expression of FZD2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
EXP |
Simvastatin results in decreased expression of GAPDH mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
EXP |
Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein |
CTD |
PMID:19842842 |
|
NCBI chr18:2,415,821...2,447,087
Ensembl chr18:2,416,552...2,446,338
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of GDI2 protein |
CTD |
PMID:20217863 |
|
NCBI chr17:70,299,177...70,325,864
Ensembl chr17:70,299,183...70,325,855
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
EXP |
Simvastatin results in increased expression of GDNF |
CTD |
PMID:20851742 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein |
CTD |
PMID:23978459 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
Simvastatin results in increased expression of GJB2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein] |
CTD |
PMID:26773838 |
|
NCBI chr 8:122,439,328...122,511,939
Ensembl chr 8:122,439,328...122,511,939
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of GPX1 mRNA Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20883752 PMID:28734741 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Simvastatin results in increased expression of GPX2 mRNA |
CTD |
PMID:18787804 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of GSK3B Simvastatin results in increased expression of GSK3B protein modified form Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:18004065 PMID:18047562 PMID:19461118 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of H2AX protein |
CTD |
PMID:20499237 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
increases expression |
EXP |
Simvastatin results in increased expression of HES5 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 5:172,364,421...172,365,188
Ensembl chr 5:172,364,421...172,365,188
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression decreases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of HIF1A protein Simvastatin results in decreased expression of HIF1A mRNA HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA] |
CTD |
PMID:18356691 PMID:21844074 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA] [Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein] |
CTD |
PMID:20519084 PMID:25412314 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance decreases activity increases expression increases activity multiple interactions affects response to substance |
ISO EXP |
HMGCR exon alternative form results in decreased susceptibility to Simvastatin Simvastatin results in decreased activity of HMGCR protein Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein Simvastatin results in increased activity of HMGCR protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] [HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 PMID:12056585 PMID:12477733 PMID:12518039 PMID:16282522 PMID:17870053 PMID:17980884 PMID:18332269 PMID:18559695 PMID:19383813 PMID:20413733 PMID:21257924 PMID:21907337 PMID:22120639 PMID:23386644 PMID:24524197 PMID:24613879 PMID:25055962 PMID:28975700 PMID:29969672 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases response to substance increases expression increases activity decreases expression increases stability |
ISO EXP |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]] HMOX1 gene mutant form results in increased susceptibility to Simvastatin Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein Simvastatin results in increased activity of HMOX1 protein Simvastatin results in decreased expression of HMOX1 mRNA Simvastatin results in increased stability of HMOX1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein] |
CTD |
PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 PMID:18787804 PMID:20368269 PMID:20594940 PMID:21844074 PMID:21910007 PMID:21925249 PMID:21968084 PMID:30513525 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf1a |
HNF1 homeobox A |
increases expression |
ISO |
Simvastatin results in increased expression of HNF1A mRNA |
CTD |
PMID:22160096 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions decreases activity |
ISO |
Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein Simvastatin results in decreased activity of HRAS |
CTD |
PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:24524197 |
|
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
affects localization |
ISO |
Simvastatin affects the localization of HSF1 protein |
CTD |
PMID:16375908 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
ISO |
Simvastatin results in increased expression of HSP90AA1 protein |
CTD |
PMID:16375908 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA4 protein |
CTD |
PMID:16375908 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
EXP |
Simvastatin results in decreased expression of HSPA8 protein |
CTD |
PMID:20217863 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Simvastatin affects the localization of HTRA2 protein |
CTD |
PMID:20045437 |
|
NCBI chr 4:113,883,671...113,886,833
Ensembl chr 4:113,883,670...113,886,994
|
|
G |
Ibsp |
integrin-binding sialoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of IBSP mRNA |
CTD |
PMID:20417880 |
|
NCBI chr14:6,801,200...6,813,987
Ensembl chr14:6,801,204...6,813,945
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form] Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form |
CTD |
PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 PMID:16193989 PMID:17277159 PMID:19166837 PMID:20863785 PMID:21764683 PMID:21874229 PMID:21994025 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
increases expression |
ISO |
Simvastatin results in increased expression of ID1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
EXP |
Simvastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of IDO1 |
CTD |
PMID:20491794 |
|
NCBI chr16:72,216,326...72,228,098
Ensembl chr16:72,216,326...72,228,098
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases secretion increases expression |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] Simvastatin results in increased secretion of IFNG protein Simvastatin results in increased expression of IFNG mRNA |
CTD |
PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 PMID:19886038 PMID:21268089 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein] |
CTD |
PMID:17327694 PMID:27734117 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression multiple interactions increases expression |
ISO |
Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein [Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] Simvastatin results in increased expression of IGF1R protein alternative form |
CTD |
PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
increases expression |
ISO |
Simvastatin results in increased expression of IGFBP6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:143,749,385...143,754,018
Ensembl chr 7:143,749,221...143,754,054
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions increases phosphorylation decreases expression |
ISO |
artemisinine inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein] Simvastatin results in decreased expression of IKBKB mRNA |
CTD |
PMID:17277159 PMID:18463201 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of IL10 Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein |
CTD |
PMID:15883752 PMID:20491794 PMID:21925249 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein] |
CTD |
PMID:15187114 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13 |
interleukin 13 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein |
CTD |
PMID:17169357 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 1:145,781,923...145,881,538
Ensembl chr 1:145,781,928...145,870,912
|
|
G |
Il17a |
interleukin 17A |
multiple interactions decreases secretion decreases expression |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA] |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il17f |
interleukin 17F |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL17F protein |
CTD |
PMID:21856936 |
|
NCBI chr 9:26,885,702...26,897,219
Ensembl chr 9:26,885,708...26,897,219
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein] |
CTD |
PMID:18660453 PMID:27377765 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:15728660 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases secretion decreases expression |
EXP ISO |
Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] Simvastatin results in decreased secretion of IL1B protein Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 PMID:18047562 PMID:18309148 PMID:18791746 PMID:19166837 PMID:19574840 PMID:20126887 PMID:20191585 PMID:21910007 PMID:22305382 PMID:27377765 PMID:30408459 PMID:31260663 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL1R2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:46,840,646...46,881,241
Ensembl chr 9:46,840,992...46,881,264
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression |
ISO |
Simvastatin results in increased expression of IL20RB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:108,745,906...108,778,561
Ensembl chr 8:108,747,204...108,777,717
|
|
G |
Il21 |
interleukin 21 |
decreases expression decreases secretion |
ISO |
Simvastatin results in decreased expression of IL21 mRNA Simvastatin results in decreased secretion of IL21 protein |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 2:123,965,021...123,972,356
Ensembl chr 2:123,965,021...123,972,356
|
|
G |
Il22 |
interleukin 22 |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL22 protein |
CTD |
PMID:21856936 |
|
NCBI chr 7:61,236,037...61,240,502
Ensembl chr 7:61,236,037...61,240,502
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of IL23A mRNA |
CTD |
PMID:18453621 PMID:22305382 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il25 |
interleukin 25 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL25 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr15:33,594,852...33,599,692
Ensembl chr15:33,596,301...33,599,685
|
|
G |
Il27 |
interleukin 27 |
increases expression increases secretion multiple interactions |
ISO |
Simvastatin results in increased expression of IL27 mRNA Simvastatin results in increased secretion of IL27 protein IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] |
CTD |
PMID:18453621 |
|
NCBI chr 1:198,003,615...198,010,112
Ensembl chr 1:198,003,683...198,008,893
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
affects expression decreases expression |
ISO |
Simvastatin affects the expression of IL2RA protein Simvastatin results in decreased expression of IL2RA mRNA |
CTD |
PMID:16387846 PMID:18453621 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il4 |
interleukin 4 |
multiple interactions decreases expression increases secretion increases expression |
ISO |
IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein Simvastatin results in increased secretion of IL4 protein Simvastatin results in increased expression of IL4 mRNA |
CTD |
PMID:17169357 PMID:18453621 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il4r |
interleukin 4 receptor |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of IL4R mRNA Simvastatin results in decreased expression of IL4RA mRNA |
CTD |
PMID:16414398 PMID:18453621 |
|
NCBI chr 1:196,942,343...196,967,221
Ensembl chr 1:196,942,364...196,967,220
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects secretion decreases secretion decreases expression increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein Simvastatin affects the secretion of IL6 protein Simvastatin results in decreased secretion of IL6 protein Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Simvastatin results in increased expression of IL6 mRNA Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] |
CTD |
PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 PMID:16511915 PMID:17075836 PMID:17641834 PMID:17729120 PMID:18203325 PMID:18453621 PMID:18504409 PMID:19001041 PMID:19166837 PMID:20065508 PMID:20126887 PMID:21994025 PMID:22305382 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:37,264,818...37,292,718
Ensembl chr13:37,266,312...37,287,458
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:21856936 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Itgal |
integrin subunit alpha L |
affects binding decreases expression multiple interactions |
ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGAL mRNA Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 PMID:15041742 PMID:16828882 |
|
NCBI chr 1:198,744,053...198,781,745
Ensembl chr 1:198,744,050...198,781,750
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] |
CTD |
PMID:16414398 PMID:21330348 PMID:21441352 |
|
NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:17428261 PMID:21874229 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb2 |
integrin subunit beta 2 |
affects binding decreases expression multiple interactions |
ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of ITGB2 mRNA Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2] Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] |
CTD |
PMID:12615677 PMID:15041742 PMID:21330348 |
|
NCBI chr20:11,777,773...11,815,647
Ensembl chr20:11,777,783...11,815,647
|
|
G |
Itgb3bp |
integrin subunit beta 3 binding protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB3BP mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:118,476,410...118,541,928
Ensembl chr 5:118,476,430...118,673,780
|
|
G |
Itgb4 |
integrin subunit beta 4 |
affects expression increases expression |
ISO |
Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein |
CTD |
PMID:14630613 PMID:19110722 |
|
NCBI chr10:104,524,000...104,560,180
Ensembl chr10:104,523,996...104,561,078
|
|
G |
Itgbl1 |
integrin subunit beta like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:110,114,148...110,378,970
Ensembl chr15:110,114,148...110,378,969
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein] |
CTD |
PMID:16534557 |
|
NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases phosphorylation decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein] Simvastatin results in decreased phosphorylation of JAK2 protein Simvastatin results in decreased expression of JAK2 mRNA |
CTD |
PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases express |